reports
Aktionärinnen und Aktionäre stimmen auf der ordentlichen Hauptversamml...
Aktionärinnen und Aktionäre stimmen auf der ordentlichen Hauptversammlung 2024 der BioNTech SE allen Tagesordnungspunkten zu MAINZ, Deutschland, 17. Mai 2024 (GLOBE NEWSWIRE) — (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) hat heute, am 17. Mai 2024, die diesjährige ordentliche Hauptversammlung abgehalten. Insgesamt waren 87,51 Prozent des Grundkapitals bei der virtuellen Versammlung vertreten. Es standen 14 Punkte auf der Tagesordnung der Hauptversammlung. Die Aktionärinnen und Aktionäre stimmten allen Beschlussvorschlägen der Verwaltung zu den zur Abstimmung stehenden Tagesordnungspu...
BioNTech SE Shareholders Approve All Agenda Items at the Annual Genera...
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024 MAINZ, Germany, May 17, 2024 (GLOBE NEWSWIRE) — (Nasdaq: BNTX, “BioNTech” or the “Company”) held its Annual General Meeting (“AGM”) today, May 17, 2024. A total of 87.51 per cent of the share capital was represented at the virtual assembly. There were 14 items on the agenda of the AGM. All resolutions proposed on the agenda items put to the vote at today’s AGM were approved by a large majority of the shareholders. “The past few years marked a leap in competence for BioNTech,” said Helmut Jeggle, Chair...
- Jacob Mekhael
Autolus 1Q24 update reiterates pipeline timelines, obe-cel data at ASC...
Autolus reported uneventful 1Q24 results, with a cash position of $758.5m (FY23: $ 239.6m), sufficient to fund the company into the first pivotal data from obe-cel (CD19 CAR-T) in autoimmune disease (we expect this to come in 2027/2028). The company reiterated pipeline timelines, with the next key event being additional analysis and longer follow up from the phase 2 (FELIX) trial of obe-cel in r/r adult ALL, expected at ASCO in June 2024, which will provide more insight into long term durability...
Autolus Therapeutics Reports First Quarter 2024 Financial Results and ...
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHATwo patients enrolled in Phase 1 Systemic Lupus Erythematosus (SLE) trial; study on track for initial data end of 2024Market Authorization Application (MAA) for obe-cel in r/r adult ALL accepted by European Medicines Agency (EMA)Conference call to be held today at 08:30 am EDT/13:30 pm BST: conference call participants should pre-register using the link at the bottom of this press ...
Transgene’s Combined General Meeting of May 15, 2024
Transgene’s Combined General Meeting of May 15, 2024 Strasbourg, France, May 15, 2024, 05:45 p.m. CEST – The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held today (May 15, 2024) at 10:00 a.m. at the Company’s headquarters (400 boulevard Gonthier d’Andernach – Parc d’Innovation – 67400 Illkirch-Graffenstaden, France). The meeting was chaired by Alessandro Riva, Chairman and CEO, to approve the Company’s financial statements for the year ended December 31, 2023, and to vote on the other resolutions submitted for approval. The replay of the Combi...
Assemblée Générale Mixte de Transgene du 15 mai 2024
Assemblée Générale Mixte de Transgene du 15 mai 2024 Strasbourg, France, le 15 mai 2024, 17 h 45 – L’Assemblée Générale Mixte (ordinaire et extraordinaire) des actionnaires de Transgene a eu lieu ce jour (15 mai 2024) à 10 h 00 au siège social de l’entreprise (400 boulevard Gonthier d’Andernach – Parc d’Innovation – 67400 Illkirch-Graffenstaden). L’Assemblée Générale Mixte a été présidée par Alessandro Riva, Président-Directeur général, afin d’approuver les comptes sociaux et consolidés de l’exercice clos le 31 décembre 2023, et de se prononcer sur l’ensemble des résolutions qui leur ont é...
- Martial Descoutures
- Oussema Denguir
Transgene : Visibilité financière et calendrier clinique confirmé
>Une visibilité financière jusqu’à fin 2025 - TNG publiait hier soir ses résultats du T1 qui se révèlent sans grande surprise. Les produits opérationnels de 1.7 M€ se décomposent essentiellement de financements publics correspondant à 25% du crédit d’impôt recherche. Le point clé reste évidemment la trésorerie du groupe qui ressort à 13.7 M€ à la fin du T1 ce qui équivaut à une consommation de trésorerie de 11.2 M€ dans l’intervalle. Aussi rappelons que TNG avait...
- Jerôme Bodin
- Thomas Zlowodzki
ODDO BHF Small & MIDCAP MORNING NEWS - 05/15/2024 Date Performance sin...
With 71% of the companies in the Stoxx 600 having released their Q1 2024 results, the picture at this stage is encouraging, with 58% of positive surprises on results. Materials and financials were the sectors that delivered the most positive surprises. If the Q4 2023 earnings season put an end to a downward revision of EPS, the Q1 2024 earnings season has triggered the start of an upward EPS revision, more markedly in the US than in Europe. In terms of sectors, re-rating effects conti...
ETL EUTELSAT COMMUNICATIONS SA
PBB DEUTSCHE PFANDBRIEFBANK AG
TNG TRANSGENE SA
F3C SFC ENERGY AG
FGA FIGEAC AERO SA
PSM PROSIEBENSAT.1 MEDIA SE
TPE PVA TEPLA AG
TRI TRIGANO SA
MBB MBB INDUSTRIES SE
DEQ DEUTSCHE EUROSHOP AG
PAT PATRIZIA AG
WLN WORLDLINE SA
DKG DEUTSCHE KONSUM REIT-AG
NHH NH HOTEL GROUP SA
CGG CGG
BSGR B&S GROUP S.A.
MEDCL MEDINCELL SA
NEXI NEXI S.P.A.
INPST INPOST S.A.
NA9 NAGARRO
HGEA HGEARS AG
TUI TUI AG
SCHOTT PHARMA AG
R3NK RENK GROUP AG
ORP ORPEA
- Jerôme Bodin
- Thomas Zlowodzki
ODDO BHF Small & MIDCAP MORNING NEWS - 15/05/2024 Date Performance dep...
Alors que 71% des sociétés du Stoxx 600 ont publié, le bilan est à ce stade positif avec 58% de surprises positives sur les résultats. Matériaux et Financières sont les secteurs ayant apporté le plus de surprises positives. Le consensus – qui avait stoppé sa baisse durant les publications T4-23, est désormais reparti à la hausse, plus nettement aux Etats-Unis qu’en Europe. Sectoriellement, les effets de rerating ont continué de dominer les révisions de BPA. - ...
ETL EUTELSAT COMMUNICATIONS SA
PBB DEUTSCHE PFANDBRIEFBANK AG
TNG TRANSGENE SA
F3C SFC ENERGY AG
FGA FIGEAC AERO SA
PSM PROSIEBENSAT.1 MEDIA SE
TPE PVA TEPLA AG
TRI TRIGANO SA
MBB MBB INDUSTRIES SE
DEQ DEUTSCHE EUROSHOP AG
PAT PATRIZIA AG
WLN WORLDLINE SA
DKG DEUTSCHE KONSUM REIT-AG
NHH NH HOTEL GROUP SA
CGG CGG
BSGR B&S GROUP S.A.
MEDCL MEDINCELL SA
NEXI NEXI S.P.A.
INPST INPOST S.A.
NA9 NAGARRO
HGEA HGEARS AG
TUI TUI AG
SCHOTT PHARMA AG
R3NK RENK GROUP AG
ORP ORPEA
- Martial Descoutures
- Oussema Denguir
Transgene : Financial visibility and clinical timetable confirmed
>Financial visibility out to end-2025 - TNG’s Q1 results, reported yesterday evening, were broadly unsurprising. Operating income of € 1.7m breaks down mainly into public financing which corresponds to 25% of the research tax credit. The key point is clearly the group’s cash which came in at € 13.7m at end-Q1, equating to cash burn of € 11.2m in the meantime. Note also that TNG had last March signed a rider to the agreement on the current account advance with th...
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate’s drug candidates have been accepted for the European Association of Hematology (EHA) 2024 Congress, taking place June 13-16, 2024 in Madrid, Spain. Two abstracts are related to SAR443579 (IPH6101), an investigational trifunctional anti-CD123 NKp46xCD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi and currently being evaluated as a monotherapy in a Sanofi-sponsored Phas...
Innate Pharma partage les abstracts sélectionnés pour le congrès 2024 ...
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui que quatre abstracts concernant des candidats-médicaments d’Innate ont été sélectionnés pour le congrès annuel de l’EHA (European Hematology Association), qui se tiendra du 13 au 16 juin 2024 à Madrid : Deux abstracts concernent SAR443579 (IPH6101), un NK Cell Engager trifonctionnel engageant les récepteurs NKp46/CD16 et ciblant CD123, issu d’une collaboration entre Innate Pharma et Sanofi, et actuellement évalué en monothérapie d...
Transgene provides business and financial update for Q1 2024
Transgene provides business and financial update for Q1 2024 TG4050: Exciting Phase I data presented at AACR 2024 demonstrating first signs of clinical benefit in adjuvant setting for head and neck cancer Phase II part of randomized trial to start in coming weeks New clinical data expected on TG4001, TG6050 and BT-001 in H2 2024 Financial visibility until Q4 2025 Strasbourg, France, May 14, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today provide...
Autolus Therapeutics to Present Three Clinical Data Updates on obecabt...
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress LONDON, May 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of three abstracts submitted to the European Hematology Association (EHA) Congress, to be held June 13-16, 2024. Oral presentation: T...
- Nicolas David
BEKB BEKAERT SA
IPH INNATE PHARMA SA CLASS A
HOT HOCHTIEF AG
CFEB COMPAGNIE D'ENTREPRISES CFE SA
INH INDUS HOLDING AG
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
TEG TAG IMMOBILIEN AG
COK CANCOM SE
AALB AALBERTS N.V.
COL INMOBILIARIA COLONIAL SOCIMI SA
MEL MELIA HOTELS INTERNATIONAL S.A.
ALM ALMIRALL SA
DUE DURR AG
BSGR B&S GROUP S.A.
S30 SOLUTIONS 30 SE
NA9 NAGARRO
HGEA HGEARS AG
FORSE FORSEE POWER SA
DEME DEME GROUP NV
- Nicolas David
BEKB BEKAERT SA
IPH INNATE PHARMA SA CLASS A
HOT HOCHTIEF AG
CFEB COMPAGNIE D'ENTREPRISES CFE SA
INH INDUS HOLDING AG
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
TEG TAG IMMOBILIEN AG
COK CANCOM SE
AALB AALBERTS N.V.
COL INMOBILIARIA COLONIAL SOCIMI SA
MEL MELIA HOTELS INTERNATIONAL S.A.
ALM ALMIRALL SA
DUE DURR AG
BSGR B&S GROUP S.A.
S30 SOLUTIONS 30 SE
NA9 NAGARRO
HGEA HGEARS AG
FORSE FORSEE POWER SA
DEME DEME GROUP NV
- Martial Descoutures
- Oussema Denguir
Innate Pharma : No surprises in Q1 results, pending the ASCO
>Financial visibility out to end-2025 - This morning, Innate Pharma published its top line and cash position for Q1 2024. The group does not yet generate recurring revenues, with revenues over the period largely stemming from the recognition of payments received from its partnerships with AstraZeneca and Sanofi coming in at € 6.6m (vs € 26m in 2023). The cash position at end-March 2024 was € 114m vs € 102.3m at end-December 2023 (without factoring in the € 4m still t...
- Martial Descoutures
- Oussema Denguir
Innate Pharma : Des résultats T1 sans surprises dans l’attente de l’AS...
>Visibilité financière jusqu’à fin 2025 - Innate Pharma publie ce matin sa topline et sa trésorerie au titre du premier trimestre 2024. La société ne réalise pas encore de CA récurrent, les revenus sur la période provenant essentiellement de reconnaissance de paiement reçus dans le cadre de ses partenariats avec AstraZeneca et Sanofi s’élèvent à 6.6 M€ (vs 26 M€ en 2023). La trésorerie à fin mars 2024 s’établit à 114 M€ contre 102.3 M€ fin décembre 2023 (sans tenir co...
Innate Pharma fait le point sur ses activités et publie ses résultats ...
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq: IPHA) (« Innate » ou la « Société ») a annoncé aujourd’hui son chiffre d’affaires et sa position de trésorerie pour les trois premiers mois de l’année 2024. « Nous poursuivons la mise en œuvre de notre stratégie qui s’appuie sur nos partenariats industriels et vise au développement de nouveaux candidats médicaments propriétaires, » commente Hervé Brailly, Président du Directoire par interim d’Innate Pharma. « Nous avons démarré l’essai clinique de notre ANKET® de seconde génération, IPH65...
Innate Pharma Reports First Quarter 2024 Business Update and Financial...
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the quarter ending March 31, 2024. “We are executing our strategy of building on our partnered drug candidates while advancing our next generation of proprietary medicines,” said Hervé Brailly, Chief Executive Officer ad interim of Innate Pharma. “Our second generation ANKET®, IPH6501 began clinical development for NHL. We presented preclinical data for IPH45, our Nectin-4 ADC, at the recently held AACR ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.